CB-020 / Caribou Biosci - LARVOL DELTA

Caribou cuts NK cell therapy program, lays off 12% of staff to fund CAR-T priorities (FierceBiotech) - "The CAR-NK program, dubbed CB-020, was an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 cell therapy aimed at solid tumors. Caribou already revealed in March that it had paused work on the program as part of a 'regular portfolio prioritization process...With the NK plans now abandoned altogether, the biotech can focus its resources on its allogeneic CAR-T platform, which Caribou noted yesterday has 'multiple milestones expected in 2024 and 2025' across its oncology and autoimmune arms...These include presenting initial dose escalation data for CB-011 in relapsed or refractory multiple myeloma by the end of this year, as well as launching a phase 1 trial of its lead asset CB-010—which is already being tested in B cell lymphoma—in lupus."

Discontinued • New P1 trial • P1 data • Lupus • Multiple Myeloma • Solid Tumor

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy (GlobeNewswire) - "Caribou Biosciences, Inc...announced target selection for CB-020, an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 (receptor tyrosine kinase like orphan receptor 1) CAR-NK cell therapy. Preclinical data on the selection of the CB-020 CAR construct and armoring strategies for Caribou’s CAR-NK cell platform will be presented today at the 12th American Association for Cancer Research and Japanese Cancer Association (AACR-JCA) Joint Conference...Results from the company’s preclinical studies suggest iPSC-derived NK cells with a knockout of CBLB (Casitas B-Lineage lymphoma proto-oncogene-B), a ubiquitin ligase that negatively regulates NK cell function, results in reduced tumor burden and increased overall survival in an in vivo solid tumor xenograft model, compared to unedited iPSC-derived NK cells."

Preclinical • Oncology • Solid Tumor

Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "CB-020: Caribou expects to announce target selection for CB-020, an iPSC-derived CAR-NK cell therapy for solid tumors, in Q4 2022. Additionally, Caribou expects to disclose armoring strategies under development for its CAR-NK cell platform in Q4 2022; CB-012: Caribou expects to submit an IND application for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (r/r AML), in 2023."

Clinical • IND • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology • Solid Tumor

Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "Anticipated Milestones for 2022 and Beyond: CB-020: Caribou expects to announce target selection for CB-020, an iPSC-derived CAR-NK cell therapy for solid tumors, in Q4 2022. Additionally, Caribou expects to disclose armoring strategies under development for its CAR-NK cell platform in Q4 2022; CB-012: Caribou expects to submit an IND application for CB-012, an anti-CLL-1 CAR-T cell therapy for r/r acute myeloid leukemia (AML), in 2023."

IND • Pipeline update • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates (Yahoo Finance) - "CB-010: Caribou is scheduled to share initial data from its ongoing ANTLER Phase 1 trial for CB-010, an anti-CD19 CAR-T cell therapy for r/r B- NHL, at EHA in June 2022; CB-011: Caribou expects to submit an IND application for CB-011, an anti-BCMA CAR-T cell therapy for r/r MM, in H2 2022; CB-020: Caribou expects to announce target selection for CB-020, an iPSC-derived CAR-NK cell therapy for solid tumors, in Q4 2022; CB-012: Caribou expects to submit an IND application for CB-012, an anti-CD371 CAR-T cell therapy for r/r AML, in 2023."

Clinical • IND • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) - "Anticipated Milestones for 2022 and Beyond...CB-010: Caribou expects to present initial data from its ongoing ANTLER Phase 1 trial for CB-010, an anti-CD19 CAR-T cell therapy, in adults with r/r B-NHL at a medical meeting in 2022; CB-011: Caribou expects to submit an IND application for CB-011, an anti-BCMA CAR-T cell therapy, in r/r MM in 2022; CB-020: Caribou expects to announce target selection for CB-020, an iPSC-derived CAR-NK cell therapy in 2022. Additionally, Caribou expects to disclose multiple armoring strategies under development for its CAR-NK platform in 2022; CB-012: Caribou expects to submit an IND application for CB-012, an anti-CD371 CAR-T cell therapy for r/r AML, in 2023."

Clinical • IND • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology